image
Consumer Defensive - Packaged Foods - NASDAQ - US
$ 11.18
1.61 %
$ 140 M
Market Cap
21.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one LFVN stock under the worst case scenario is HIDDEN Compared to the current market price of 11.2 USD, LifeVantage Corporation is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one LFVN stock under the base case scenario is HIDDEN Compared to the current market price of 11.2 USD, LifeVantage Corporation is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one LFVN stock under the best case scenario is HIDDEN Compared to the current market price of 11.2 USD, LifeVantage Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
200 M REVENUE
-6.20%
4.33 M OPERATING INCOME
1.71%
2.94 M NET INCOME
15.63%
12.2 M OPERATING CASH FLOW
78.63%
-2.24 M INVESTING CASH FLOW
26.61%
-14.4 M FINANCING CASH FLOW
-511.67%
67.8 M REVENUE
43.52%
3.43 M OPERATING INCOME
33.39%
2.55 M NET INCOME
39.65%
9.2 M OPERATING CASH FLOW
1677.87%
-492 K INVESTING CASH FLOW
-42.61%
-1.4 M FINANCING CASH FLOW
23.41%
Balance Sheet LifeVantage Corporation
image
Current Assets 37.6 M
Cash & Short-Term Investments 16.9 M
Receivables 3.26 M
Other Current Assets 17.5 M
Non-Current Assets 22.7 M
Long-Term Investments 0
PP&E 17.4 M
Other Non-Current Assets 5.27 M
28.00 %5.41 %29.02 %28.83 %8.74 %
Current Liabilities 22.3 M
Accounts Payable 5.85 M
Short-Term Debt 3.62 M
Other Current Liabilities 12.8 M
Non-Current Liabilities 12 M
Long-Term Debt 11.8 M
Other Non-Current Liabilities 198 K
17.06 %10.56 %37.41 %34.40 %
EFFICIENCY
Earnings Waterfall LifeVantage Corporation
image
Revenue 200 M
Cost Of Revenue 41.4 M
Gross Profit 159 M
Operating Expenses 154 M
Operating Income 4.33 M
Other Expenses 1.4 M
Net Income 2.94 M
RATIOS
79.30% GROSS MARGIN
79.30%
2.16% OPERATING MARGIN
2.16%
1.47% NET MARGIN
1.47%
11.30% ROE
11.30%
4.87% ROA
4.87%
7.03% ROIC
7.03%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis LifeVantage Corporation
image
Net Income 2.94 M
Depreciation & Amortization 3.58 M
Capital Expenditures -2.24 M
Stock-Based Compensation 3.28 M
Change in Working Capital 2.38 M
Others 2.14 M
Free Cash Flow 9.95 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets LifeVantage Corporation
image
Wall Street analysts predict an average 1-year price target for LFVN of $30.3 , with forecasts ranging from a low of $26 to a high of $35 .
LFVN Lowest Price Target Wall Street Target
26 USD 132.56%
LFVN Average Price Target Wall Street Target
30.3 USD 171.32%
LFVN Highest Price Target Wall Street Target
35 USD 213.06%
Price
Max Price Target
Min Price Target
Average Price Target
4. DIVIDEND ANALYSIS
0.23% DIVIDEND YIELD
0.04 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.03
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership LifeVantage Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
365 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
3.63 K USD 1
3-6 MONTHS
10.8 K USD 2
6-9 MONTHS
3.61 K USD 1
9-12 MONTHS
7. News
LifeVantage Corporation (LFVN) Q3 2025 Earnings Call Transcript LifeVantage Corporation (NASDAQ:LFVN ) Q3 2025 Results Conference Call May 6, 2025 4:30 PM ET Company Participants Reed Anderson - Managing Director-ICR Steve Fife - President and Chief Executive Officer Carl Aure - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Doug Lane - Water Tower Research Operator Good day, ladies and gentlemen. Thank you for standing by. seekingalpha.com - 1 week ago
LifeVantage Declares Quarterly Dividend SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. globenewswire.com - 1 week ago
LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025 SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. globenewswire.com - 1 week ago
LifeVantage: Activation Of Shareholder Value LifeVantage (LFVN) is a mispriced opportunity with potential for >15% IRR, driven by its new GLP-1 product suite and turnaround signals. LFVN's valuation is attractive at ~6x EV/EBITDA and a Fwd PEG of 0.15x, trading below sector median despite strong growth potential. The company's revamped business model and compensation package have increased active accounts by 25%, indicating early signs of success turnaround and enhanced sales outreach which the market is not reacting. seekingalpha.com - 2 weeks ago
Global Convention 2025 Empowers Consultants to ‘Go Further' with Exclusive Trainings, Product Announcements, and New Incentives to Drive Growth SALT LAKE CITY, April 28, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of their annual Global Convention, held April 24-26, 2025, in Salt Lake City, Utah. Thousands of independent LifeVantage Consultants from around the world gathered at the Salt Palace Convention Center to participate in the multi-day event. globenewswire.com - 3 weeks ago
LifeVantage to Announce Third Quarter Fiscal Year 2025 Results on May 6, 2025 SALT LAKE CITY, April 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its third quarter ended March 31, 2025, after the stock market closes on Tuesday, May 6, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. globenewswire.com - 3 weeks ago
LifeVantage Expands Global Reach with International Launch of the MB System™ SALT LAKE CITY, March 17, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation ® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is extending its groundbreaking MindBody GLP-1 System™ to international markets. This expansion comes after a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024, in the U.S., largely driven by the system's success, and clinical data on that formula reinforcing its effectiveness in supporting GLP-1 production. globenewswire.com - 2 months ago
LifeVantage Announces Launch of LV360 and Evolve Compensation Plan in Philippines, Taiwan, Hong Kong, and Singapore Markets SALT LAKE CITY, March 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation ®  (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful launch of the Evolve Compensation Plan and other LV360 initiatives into the Philippines, Taiwan, Hong Kong, and Singapore. The transition went into effect in these markets on March 1, 2025, after the successful launch of LV360 into Canada, Mexico, and Europe last February, and the launch in the US, Australia, New Zealand and Japan in March 2023. globenewswire.com - 2 months ago
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to hit the market and disrupt the medical sector. These treatments are permitted when drugs are listed on the FDA's list of drug shortages. marketbeat.com - 3 months ago
LifeVantage: Post-Earnings Selloff Provides Buying Opportunity LifeVantage Corporation's Q2/FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. LFVN revenues jumped by more than 40% on a sequential basis, while free cash flow of $8.7 million represented a new multi-year high. However, elevated commissions and incentive expenses impacted profitability, thus resulting in a rather mediocre Adjusted EBITDA margin of 9.6%. seekingalpha.com - 3 months ago
LifeVantage Corporation (LFVN) Q2 2025 Earnings Call Transcript LifeVantage Corporation (NASDAQ:LFVN ) Q2 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Reed Anderson – Managing Director-ICR Steve Fife – President and Chief Executive Officer Carl Aure – Chief Financial Officer Conference Call Participants Aaron Wukmir – Lake Street Capital Markets Alex Fuhrman – Craig-Hallum Capital Group Doug Lane – Water Tower Research Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to today's conference call to discuss LifeVantage's Second Quarter of Fiscal 2025 Results. seekingalpha.com - 3 months ago
LifeVantage Declares Quarterly Dividend SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.04 per share of common stock, which will be paid March 17, 2025 to all stockholders of record at the close of business on March 3, 2025. globenewswire.com - 3 months ago
8. Profile Summary

LifeVantage Corporation LFVN

image
COUNTRY US
INDUSTRY Packaged Foods
MARKET CAP $ 140 M
Dividend Yield 0.23%
Description LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.
Contact 3300 North Triumph Boulevard, Lehi, UT, 84043 https://www.lifevantage.com
IPO Date April 7, 1994
Employees 222
Officers Ms. Kristen Cunningham Chief Sales Officer Mr. Steven R. Fife CPA President, Chief Executive Officer & Director Mr. Carl A. Aure CPA Chief Financial Officer Ms. Alissa Neufeld J.D. General Counsel & Corporate Secretary Ms. Michelle Oborn-Virchow Chief People Officer Mr. Robert Harris Chief Digital Officer Ms. Julie Boyster Chief Marketing Officer Mr. Todd Thompson Chief Information & Innovation Officer